Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model.
Bessière P, Wasniewski M, Picard-Meyer E, Servat A, Figueroa T, Foret-Lucas C, Coggon A, Lesellier S, Boué F, Cebron N, Gausserès B, Trumel C, Foucras G, Salguero FJ, Monchatre-Leroy E, Volmer R.
Bessière P, et al. Among authors: foucras g.
PLoS Pathog. 2021 Aug 9;17(8):e1009427. doi: 10.1371/journal.ppat.1009427. eCollection 2021 Aug.
PLoS Pathog. 2021.
PMID: 34370799
Free PMC article.